Instil Bio Presents Subset Analysis Of Patients With Checkpoint-Refractory Advanced Melanoma From Compassionate Use Study At 2021 ESMO Congress
September 16, 7:04 AM
Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, announced
September 16, 6:57 AM
Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share.
August 13, 5:18 AM
Baird analyst Jack Allen initiates coverage on Instil Bio (NASDAQ:TIL) with a Outperform rating and announces Price Target of $34.
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
May 14, 7:59 AM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)